Tags

Type your tag names separated by a space and hit enter

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
N Engl J Med. 2004 Mar 18; 350(12):1200-10.NEJM

Abstract

BACKGROUND

The effect of adjuvant treatment on survival in pancreatic cancer is unclear. We report the final results of the European Study Group for Pancreatic Cancer 1 Trial and update the interim results.

METHODS

In a multicenter trial using a two-by-two factorial design, we randomly assigned 73 patients with resected pancreatic ductal adenocarcinoma to treatment with chemoradiotherapy alone (20 Gy over a two-week period plus fluorouracil), 75 patients to chemotherapy alone (fluorouracil), 72 patients to both chemoradiotherapy and chemotherapy, and 69 patients to observation.

RESULTS

The analysis was based on 237 deaths among the 289 patients (82 percent) and a median follow-up of 47 months (interquartile range, 33 to 62). The estimated five-year survival rate was 10 percent among patients assigned to receive chemoradiotherapy and 20 percent among patients who did not receive chemoradiotherapy (P=0.05). The five-year survival rate was 21 percent among patients who received chemotherapy and 8 percent among patients who did not receive chemotherapy (P=0.009). The benefit of chemotherapy persisted after adjustment for major prognostic factors.

CONCLUSIONS

Adjuvant chemotherapy has a significant survival benefit in patients with resected pancreatic cancer, whereas adjuvant chemoradiotherapy has a deleterious effect on survival.

Authors+Show Affiliations

Department of Surgery, Liverpool University, Liverpool, United Kingdom.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15028824

Citation

Neoptolemos, John P., et al. "A Randomized Trial of Chemoradiotherapy and Chemotherapy After Resection of Pancreatic Cancer." The New England Journal of Medicine, vol. 350, no. 12, 2004, pp. 1200-10.
Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200-10.
Neoptolemos, J. P., Stocken, D. D., Friess, H., Bassi, C., Dunn, J. A., Hickey, H., Beger, H., Fernandez-Cruz, L., Dervenis, C., Lacaine, F., Falconi, M., Pederzoli, P., Pap, A., Spooner, D., Kerr, D. J., & Büchler, M. W. (2004). A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. The New England Journal of Medicine, 350(12), 1200-10.
Neoptolemos JP, et al. A Randomized Trial of Chemoradiotherapy and Chemotherapy After Resection of Pancreatic Cancer. N Engl J Med. 2004 Mar 18;350(12):1200-10. PubMed PMID: 15028824.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. AU - Neoptolemos,John P, AU - Stocken,Deborah D, AU - Friess,Helmut, AU - Bassi,Claudio, AU - Dunn,Janet A, AU - Hickey,Helen, AU - Beger,Hans, AU - Fernandez-Cruz,Laureano, AU - Dervenis,Christos, AU - Lacaine,François, AU - Falconi,Massimo, AU - Pederzoli,Paolo, AU - Pap,Akos, AU - Spooner,David, AU - Kerr,David J, AU - Büchler,Markus W, AU - ,, PY - 2004/3/19/pubmed PY - 2004/3/24/medline PY - 2004/3/19/entrez SP - 1200 EP - 10 JF - The New England journal of medicine JO - N. Engl. J. Med. VL - 350 IS - 12 N2 - BACKGROUND: The effect of adjuvant treatment on survival in pancreatic cancer is unclear. We report the final results of the European Study Group for Pancreatic Cancer 1 Trial and update the interim results. METHODS: In a multicenter trial using a two-by-two factorial design, we randomly assigned 73 patients with resected pancreatic ductal adenocarcinoma to treatment with chemoradiotherapy alone (20 Gy over a two-week period plus fluorouracil), 75 patients to chemotherapy alone (fluorouracil), 72 patients to both chemoradiotherapy and chemotherapy, and 69 patients to observation. RESULTS: The analysis was based on 237 deaths among the 289 patients (82 percent) and a median follow-up of 47 months (interquartile range, 33 to 62). The estimated five-year survival rate was 10 percent among patients assigned to receive chemoradiotherapy and 20 percent among patients who did not receive chemoradiotherapy (P=0.05). The five-year survival rate was 21 percent among patients who received chemotherapy and 8 percent among patients who did not receive chemotherapy (P=0.009). The benefit of chemotherapy persisted after adjustment for major prognostic factors. CONCLUSIONS: Adjuvant chemotherapy has a significant survival benefit in patients with resected pancreatic cancer, whereas adjuvant chemoradiotherapy has a deleterious effect on survival. SN - 1533-4406 UR - https://www.unboundmedicine.com/medline/citation/15028824/A_randomized_trial_of_chemoradiotherapy_and_chemotherapy_after_resection_of_pancreatic_cancer_ L2 - http://www.nejm.org/doi/full/10.1056/NEJMoa032295?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -